GNNSF (Genscript Biotech) GF Value Rank: 10 (As of Jul. 31, 2026) — 150% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GNNSF Genscript Biotech Corp GNNSF
72 GF Score
Price $2.00
GF Value $2.31
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Genscript Biotech GF Value Rank?

Genscript Biotech GNNSF +9.89% 72 GF Value Rank is 10 as of Jul. 31, 2026, which is 150% above its 10-year median of 4.00. GuruFocus rates GNNSF with a GF Score™ of 72/100 and a GF Value™ of $2.31 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Genscript Biotech has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Genscript Biotech GF Value Rank Related Terms


GNNSF vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, Genscript Biotech's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genscript Biotech GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's GF Value Rank falls into.


GNNSF
72GF Score
Genscript Biotech Corp GNNSF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Genscript Biotech (GNNSF) has a GF Value Rank of 10 as of Jul. 31, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Genscript Biotech and its competitors. This is 150% above median its historical median of 4.00. Over the past decade, Genscript Biotech's GF Value Rank has ranged from 1.00 to 10.00.
Is Genscript Biotech's GF Value Rank too high?
Genscript Biotech's current GF Value Rank of 10 is 150% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Genscript Biotech has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's GF Value Rank compare to VRTX and REGN?
Genscript Biotech's GF Value Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Genscript Biotech's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current GF Value Rank is 10, which is 150% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.31, compared to a current price of $2.00 — trading 13.4% below its estimated fair value. The current GF Value Rank is 10, which is 150% above median its 10-year median of 4.00. Genscript Biotech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current GF Value Rank is 10 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (GNNSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of $2.00 is trading 13.4% below its estimated GF Value™ of $2.31. GuruFocus considers Genscript Biotech to be Modestly Undervalued.

Key valuation signals for GNNSF:

  • GF Value Rank: 10 (150% above median its 10-year median of 4.00)
  • GF Value™: $2.31 vs. price of $2.00 (13.4% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genscript Biotech Business Description

Other Exchanges 01548:Hong KongG51:Germany
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
72GF Score

Get the complete analysis for GNNSF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$2.31
GF Value